Regeneron expects $127 million Q2 2026 acquired IPR&D charge, a $1.00 per-share hit
Regeneron said its second quarter 2026 results will include an acquired in-process research and development (IPR&D) charge of about $127 million pre-tax, tied to up-front and opt-in payments under collaboration and licensing agreements. The company expects the charge to reduce both GAAP and non-GAAP net income per diluted share by about $1.00 for the quarter. The figures are preliminary and unaudited, and the company does not forecast such charges.
Key points
- Expected acquired IPR&D charge of about $127 million on a pre-tax basis for Q2 2026
- Expected impact of about $1.00 per diluted share on both GAAP and non-GAAP net income
- Charge relates to up-front and opt-in payments under collaboration and licensing agreements
- Q2 2026 results have not been finalized and remain subject to closing procedures
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:21 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 06, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.